Advertisement
Organisation › Details
Catalent Inc. (NYSE: CTLT)
Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of more than 7,000 products annually. Catalent’s expert workforce exceeds 18,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. *
Start | 2019-04-15 existent | |
Group | Catalent (Group) | |
Industry | contract manufacturing (drugs) | |
Industry 2 | drug delivery technology (drug formulation technology) | |
Person | Chiminski, John (Catalent 201904 CEO) | |
Street | 14 Schoolhouse Road | |
City | 08873 Somerset, NJ | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | H: 10,001 to 50,00 (2022-04-06) |
Currency | USD | |
Annual sales | 4,000,000,000 (revenue, consolidated (FY2021) 2021-12-31) | |
* Document for »About Section«: Catalent, Inc.. (4/6/22). "Press Release: Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe". Somers, NJ. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Catalent (Group)
- [1] Abzena Ltd.. (6/6/23). "Press Release: Abzena Appoints Thomas Castellano as Chief Financial Officer". San Diego, CA....
- [2] Catalent, Inc.. (4/6/22). "Press Release: Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe". Somers, NJ....
- [3] Oxford Biomedica plc. (6/8/20). "Press Release: Oxford Biomedica Signs Five Year Collaboration Agreement with the Vaccines Manufacturing and Innovation Centre". Oxford....
- [4] Catalent, Inc.. (4/15/19). "Press Release: Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion". Somerset, NJ & Baltimore, MD....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top